首页> 外文期刊>The Journal of Infectious Diseases >Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis.
【24h】

Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis.

机译:通过单核细胞趋化蛋白-1合成的抑制剂bindarit在急性基孔肯雅病毒病小鼠模型中预防关节炎和肌炎。

获取原文
获取原文并翻译 | 示例
           

摘要

Chikungunya virus (CHIKV) is associated with outbreaks of infectious rheumatic disease in humans. Using a mouse model of CHIKV arthritis and myositis, we show that tumor necrosis factor-alpha, interferon-gamma, and monocyte chemotactic protein 1 (MCP-1) were dramatically induced in tissues from infected mice. The same factors were detected in the serum of patients with CHIKV-induced polyarthralgia and polyarthritis, with MCP-1 levels being particularly elevated. Bindarit (MCP inhibitor) treatment ameliorated CHIKV disease in mice. Histological analysis of muscle and joint tissues showed a reduction in inflammatory infiltrate in infected mice treated with bindarit. These results suggest that bindarit may be useful in treating CHIKV-induced arthritides in humans.
机译:基孔肯雅病毒(CHIKV)与人类传染性风湿病的爆发有关。使用CHIKV关节炎和肌炎的小鼠模型,我们显示出肿瘤坏死因子-α,干扰素-γ和单核细胞趋化蛋白1(MCP-1)在感染小鼠的组织中被大大诱导。在CHIKV诱发的多关节痛和多关节炎患者的血清中检测到相同的因素,其中MCP-1水平特别升高。 Bindarit(MCP抑制剂)治疗可改善小鼠的CHIKV疾病。肌肉和关节组织的组织学分析表明,用必达利治疗的感染小鼠的炎症浸润减少。这些结果表明,必达利可用于治疗人的CHIKV诱导的关节炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号